Similarly, Jin et al. reported an imbalance between CD226 and TIGIT expression on γδ T cells in acute myeloid leukemia patients, with a reduction in CD226+ γδ T cells and an increase in TIGIT+ γδ T cells, suggesting a potential immune checkpoint barrier contributing to poor prognosis and T cell dysfunction [59]. The gene discussed is TIGIT; the disease is acute myeloid leukemia.